GRAND PHARM. GRP. HD-01
Grand Pharmaceutical Group Limited, an investment holding company, engages in the research and development, manufacture, and sale of pharmaceutical preparations and medical devices, biotechnology and healthcare products, and pharmaceutical raw materials. The company offers respiratory, ophthalmology, cerebro-cardiovascular emergency, and biotechnology related products. It manufactures and sells p… Read more
GRAND PHARM. GRP. HD-01 (MX6A) - Net Assets
Latest net assets as of : €- EUR
Based on the latest financial reports, GRAND PHARM. GRP. HD-01 (MX6A) has net assets worth €- EUR as of .
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€-) and total liabilities (€-). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €- |
| % of Total Assets | 0% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
GRAND PHARM. GRP. HD-01 - Net Assets Trend (None–None)
This chart illustrates how GRAND PHARM. GRP. HD-01's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for GRAND PHARM. GRP. HD-01 (None–None)
The table below shows the annual net assets of GRAND PHARM. GRP. HD-01 from None to None.
| Year | Net Assets | Change |
|---|---|---|
| No yearly data available. | ||
Equity Component Analysis
This analysis shows how different components contribute to GRAND PHARM. GRP. HD-01's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- No equity composition insights available.
GRAND PHARM. GRP. HD-01 Competitors by Market Cap
The table below lists competitors of GRAND PHARM. GRP. HD-01 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
PageGroup plc
PINK:MPGPF
|
$986.99 Million |
|
Fincantieri S.p.A
PINK:FNCNF
|
$987.15 Million |
|
Srisawad Corporation Public Company Limited
BK:SAWAD-R
|
$987.24 Million |
|
Shanghai Bailian Group Co Ltd A
SHG:600827
|
$987.40 Million |
|
Kunshan Kersen Science & Tech
SHG:603626
|
$986.15 Million |
|
Redde Northgate PLC
F:21W
|
$985.84 Million |
|
COFCO Capital Holdings Co Ltd
SHE:002423
|
$985.29 Million |
|
Semitronix Corp. A
SHE:301095
|
$984.90 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GRAND PHARM. GRP. HD-01's equity between the two most recent reporting periods.
Insufficient data available to analyze equity growth attribution.
Book Value vs Market Value Analysis
This analysis compares GRAND PHARM. GRP. HD-01's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Insufficient data available to analyze book value vs market value.
Capital Efficiency Dashboard
This dashboard shows how efficiently GRAND PHARM. GRP. HD-01 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Insufficient data available to analyze capital efficiency metrics.
Industry Comparison
This section compares GRAND PHARM. GRP. HD-01's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,244,379,027
- Average return on equity (ROE) among peers: -92.52%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GRAND PHARM. GRP. HD-01 (MX6A) | €- | N/A | N/A | $986.35 Million |
| 26U (26U) | $6.75 Million | -514.32% | 1.08x | $248.33K |
| 27N0 (27N0) | $11.56 Million | -0.93% | 0.00x | $4.66K |
| China Resources Pharmaceutical Group Limited (640) | $90.18 Billion | 4.60% | 1.68x | $940.63 Million |
| CIG WIRELESS (6CW) | $27.09 Million | -110.19% | 3.19x | $56.65 Million |
| Solasia Pharma K.K (9SO) | $1.16 Billion | -167.91% | 0.18x | $34.42 Million |
| Apontis Pharma AG (APPH) | $3.46 Million | -34.21% | 7.59x | $11.70 Million |
| Akebia Therapeutics Inc (AX9) | $635.93 Million | -22.58% | 0.57x | $283.56 Million |
| Biofrontera AG (B8FK) | $-12.89 Million | 0.00% | 0.00x | $3.86 Million |
| AVALA RES (CVJ) | $91.87 Million | -27.32% | 0.11x | $113.22K |
| Deciphera Pharmaceuticals Inc (D05) | $341.69 Million | -52.37% | 0.33x | $2.11 Billion |